Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: Enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis

Hepatology

Volumn 51, Issue 4, 2010, Pages 1190-1199

  Zhang, Xuequn ^a,b   Yang, Juntao ^a   Guo, Yuanbiao ^a   Ye, Hua ^b   Yu, Chaohui ^b   Xu, Chengfu ^b   Xu, Lei ^b   Wu, Songfeng ^a   Sun, Wei ^a   Wei, Hangdong ^a   Gao, Xue ^a   Zhu, Yunping ^a   Qian, Xiaohong ^a   Jiang, Ying ^a   Li, Youming ^b   He, Fuchu ^a,c  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENOYL COENZYME A HYDRATASE; FATTY ACID; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOWN REGULATION; FUNCTIONAL PROTEOMICS; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID STORAGE; LIVER BIOPSY; LIVER CELL; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; DIETARY FATS; DISEASE MODELS, ANIMAL; ENOYL-COA HYDRATASE; FATTY LIVER; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77950625001     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23486     Document Type: Article

References (34)

1. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
2. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149.
3. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-514.
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCul-lough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
6. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114: 842-845.
7. Mezey E. Dietary fat and alcoholic liver disease. HEPATOLOGY 1998;28: 901-905.
8. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. HEPATOLOGY 2003;37:909-916.
9. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004;79:502-509.
10. Hanash S. Disease proteomics. Nature 2003;422:226-232.
11. Unlü M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18:2071-2077.
12. Sun W, Xing B, Sun Y, Du X, Lu M, Hao C, et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophore-sis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 2007;6:1798-1808.
13. Zhang X, Guo Y, Song Y, Sun W, Yu C, Zhao X, et al. Proteomic analysis of individual variation in normal livers of human beings using difference gel electrophoresis. Proteomics 2006;6:5260-5268.
14. Gómez-Lechón MJ, Donato MT, Mart́nez-Romero A,Jiménez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007;165:106-116.
15. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
16. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32:107-108.
17. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003;100:3065-3070.
18. Van Greevenbroek MM, Vermeulen VM, De Bruin TW. Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. J Lipid Res 2004;45:1148-1154.
19. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, et al. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver. disease. HEPATOLOGY 2009;49:1375-1384.
20. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28.
21. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. HEPATOLOGY 2003;37: 1202-1219.
22. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. HEPATOLOGY 2006;44:27-33.
23. Rao MS, Reddy JK. PPARalpha in the pathogenesis of fatty liver disease. HEPATOLOGY 2004;40:783-786.
24. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome pro-liferator-activated receptor alpha: an adaptive metabolic. Annu Rev Nutr. 2001;21:193-230.
25. Linhart HG, Ishimura-Oka K, DeMayo F, Kibe T, Repka D, Poindexter B, et al. C/EBPalpha is required for differentiation of white, but not brown, adipose tissue. Proc Natl Acad Sci USA 2001;98:12532-12537.
26. Matsusue K, Gavrilova O, Lambert G, Brewer HB Jr, Ward JM, Inoue Y, et al. Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol Endocrinol 2002;18:2751-2764.
27. Qiao L, MacLean PS, You H, Schaack J, Shao J. Knocking down liver ccaat/enhancer-binding protein alpha by adenovirus-transduced silent interfering ribonucleic acid improves hepatic gluconeogenesis and lipid ho-meostasis in db/db mice. Endocrinology 2006;147:3060-3069.
28. Zhang D, Liu ZX, Choi CS, Tian L, Kibbey R, Dong J, et al. Mitochon-drial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci USA 2007;104:17075-17080.
29. Tolwani RJ, Hamm DA, Tian L, Sharer JD, Vockley J, Rinaldo P, et al. Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. PLoS Genet 2005;1:e23.
30. Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005;128:1381-1390.
31. Shulman GI. Cellular mechanismsof insulin resistance.J Clin Invest 2000; 106:171-176.
32. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzi-oni M, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006;169:846-860.
33. Safwat GM, Pisanò S, D'Amore E, Borioni G, Napolitano M, Kamal AA, et al. Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect? Nutrition 2009;25:1157-1168.
34. Omagari K, Kato S, Tsuneyama K, Inohara C, Kuroda Y, Tsukuda H, et al. Effects of a long-term high-fat diet and switching from a high-fat to low-fat, standard diet on hepatic fat accumulation in Sprague-Dawley rats. Dig Dis Sci 2008;53:3206-3212.